Golden Biotechnology Corp (GBC, 國鼎) plans to apply for emergency use authorization in the US for its experimental COVID-19 drug after positive results in its phase 2 clinical trials, the company said.
GBC on Wednesday announced some of the results from randomized, double-blind and placebo-controlled studies in phase 2 clinical trials of its COVID-19 oral drug antroquinonol, dubbed Hocena, for the treatment of people hospitalized with mild-to-moderate COVID-19 symptoms.
In the trials, 97.9 percent of people recovered by the 14th day after being given the drug and all participants recovered by the 28th day, GBC spokesman Alan Tseng (曾木增) said yesterday.
Photo: Chen Yung-chi, Taipei Times
“Recovered” meant that participants did not have respiratory failure, and thus did not require ventilation, high-flow oxygen or extracorporeal membrane oxygenation, Tseng said.
The median length of hospitalization for those in the experimental group was four days, 20 percent shorter than for those in the control group, the company said.
Of the five participants in intensive care due to serious COVID-19 symptoms, the median length of treatment for those given the drug was 13.5 days, 9.5 days shorter than for those given the placebo, it said.
The median period in which those in the experimental group first tested negative for COVID-19 after receiving the drug was 14 days, the company said.
The full test results would be disclosed after GBC receives a report from Labcorp Drug Development, a US-based contract research organization that helped conduct the human trials, the company said.
The trials began in October 2020 and were conducted in Argentina, Peru and the US, it said.
GBC recruited 124 participants, despite initially planning to enroll 174.
“But the results of phase 2 clinical trials should be meaningful statistically once the number of participants exceeds 100,” GBC chairman Liu Sheng-yung (劉勝勇) said.
“Over the past year, the coronavirus mutated quickly and we have witnessed breakthrough infections, which occur when a fully vaccinated person contracts the disease,” Liu said, adding that the ratio of people with breakthrough infections to all of those infected with COVID-19 had surpassed 60 percent and is expected to continue rising.
“However, so far, no company has claimed that its drug can repel breakthrough infections, so we think it is necessary to test our drug against breakthrough infections in our phase 3 clinical trials,” Liu said. “So we are under time pressure” to finish phase 2 trials and begin phase 3.
GBC was the nation’s second biotech company to complete phase 2 human trials on an oral COVID-19 treatment, after Senhwa Biosciences Inc (生華科) in October last year.
GBC shares yesterday surged 50 percent to NT$212.22 on the Emerging Stock Board, up from NT$54 a year earlier, Taipei Exchange data showed.
A signaling system malfunction disrupted high-speed rail (HSR) services beginning at 8am today, with trains temporarily reduced to three northbound and three southbound trains per hour as authorities conduct inspections. The malfunction occurred on a section of track in Miaoli County during pre-operation checks early this morning, forcing northbound and southbound trains to use a single track, the HSR operator said. The regular schedule has been replaced with three hourly trains offering only nonreserved seating in each direction, stopping at every station, it said, adding that business class cars would still have reserved seating. Departures from terminal stations are scheduled at the top
DRONE CENTRAL: Taiwan aims to become Asia’s democratic hub for drones, with most exports focused on high-quality military-grade models, an official said Taiwan’s drone industry is expected to expand significantly by 2030, producing 100,000 units per month and exporting half of them, the Ministry of Economic Affairs said yesterday. Current drone production capacity is about 15,000 units per month, but the industry can quickly scale up as demand increases, Industrial Development Administration Director-General Chiou Chyou-huey (邱求慧) told a news conference in Taipei. Taiwan’s drone output grew 2.5-fold last year to NT$12.9 billion (US$408.3 million) under a government program to develop the uncrewed vehicle sector, he said. The Executive Yuan in October last year approved plans to invest NT$44.2 billion into domestic production of uncrewed aerial
VERBOSE VESSELS: A CGA cutter and a China Coast Guard exchanged verbal barbs for more than a day in Taiwanese-controlled waters before the Chinese vessel left The Taiwanese and Chinese coast guards had a standoff near the strategically located Pratas Islands (Dongsha Islands, 東沙群島) in the north of the South China Sea, the Coast Guard Administration (CGA) said yesterday. The two sides engaged in intense radio exchanges over sovereignty claims during the 33-hour standoff. China Coast Guard vessel 3501 eventually left the restricted waters, 26.6 nautical miles (49.2km) west of the Pratas Islands, at 5pm yesterday, the CGA said. Lying approximately between southern Taiwan and Hong Kong, the Taiwan-controlled Pratas are seen by some security experts as vulnerable to Chinese attack due to their distance — more than
WARNING: China should stop engaging in actions that undermine regional peace and stability, as it would only build resentment among people across the Strait, the CGA said China has deployed more than 100 navy, coast guard and other vessels in waters from the Yellow Sea to the South China Sea and the western Pacific since US President Donald Trump and Chinese President Xi Jinping (習近平) met in Beijing, National Security Council Secretary-General Joseph Wu (吳釗燮) said yesterday. “In this part of the world, #China is the one & only PROBLEM wrecking the #StatusQuo & threatening regional peace & stability,” Wu wrote on X. In a separate post, he said Beijing was coercing Taiwan’s maritime domain, calling it illegal and provocative, after the Coast Guard Administration (CGA) expelled a
RSS